Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 16/20 | 0.52 |
| ▸ | LOX | P28300 | 5/20 | 0.52 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.52 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25229826 | 0.98 | LOXL2 (0.50) | LOXL2LOXLOXL3MYCROCK1 | |
| Hydrochloric Acid SCHEMBL31450293 | 0.98 | LOXL2 (0.50) | LOXL2LOXLOXL3MYCROCK1 | |
| SCHEMBL14614499 | 0.85 | LOXL2 (0.45) | LOXL2LOXLOXL3MYCXDH | |
| Trifluoroacetic Acid SCHEMBL17371985 | 0.84 | LOXL2 (0.46) | LOXL2LOXLOXL3MYC | |
| Hydrochloric Acid SCHEMBL2020607 | 0.83 | LOXL2 (0.44) | LOXL2LOXLOXL3MYC | |
| SCHEMBL451725 | 0.80 | MYC (0.39) | LOXL2LOXMYCXDHABCG2 | |
| SCHEMBL3302943 | 0.80 | NOS3 (0.52) | MYCXDHABCG2 | |
| SCHEMBL6466230 | 0.80 | MYC (0.39) | LOXL2LOXLOXL3MYCXDH | |
| SCHEMBL451724 | 0.80 | MYC (0.39) | MYCXDHABCG2 | |
| SCHEMBL2642689 | 0.80 | MYC (0.39) | MYCXDHABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| CN-119638668-A | Topiramate preparation method of special | 山东新时代药业有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2025-03-06 | — | — | US | disclosed |
| EP-4452944-A1 | CYCLOPROPYL COMPOUNDS | Icagen, LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240336571-A1 | NOVEL CYCLOPROPYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2024-10-10 | — | — | US | disclosed |
| EP-4433453-A1 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | Icagen, LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| CN-118525003-A | Novel heteroaryl urea compounds as KV7.2 inhibitors | 伊卡根有限责任公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2023091554-A9 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | ICAGEN, LLC (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023121992-A1 | CYCLOPROPYL COMPOUNDS | ICAGEN, LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023091554-A1 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | ICAGEN, LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1598349-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-23 | — | — | EP | disclosed |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | XIN ZHILI (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | KOSOGOF CHRISTI (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005030734-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS | ABBOTT LABORATORIES (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A43, F12 | LOXL2 3167/4885LOX 3544/4885LOXL3 1161/4885 |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | LOXL2 4172/4885LOX 3007/4885LOXL3 4399/4885 |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | LOXL2 4394/4885LOX 3351/4885LOXL3 4462/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | LOXL2 3298/4885LOX 1428/4885LOXL3 1645/4885 |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | GPR119, GIPR, GCGR | LOXL2 4447/4885LOX 2945/4885LOXL3 4160/4885 |
| US-20240336571-A1 | NOVEL CYCLOPROPYL COMPOUNDS | C1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR1 | LOXL2 4525/4885LOX 4419/4885LOXL3 3535/4885 |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | GCKR, GCK, HK2 | LOXL2 2252/4885LOX 1812/4885LOXL3 2209/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | LOXL2 1949/4885LOX 1178/4885LOXL3 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.